NICE draft type 2 diabetes guidelines: A cause for concern

The Lancet Diabetes and Endocrinology

Volumn 3, Issue 6, 2015, Pages 403-405

  Barnett, Anthony H ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN DERIVATIVE; ISOPHANE INSULIN; METFORMIN; PIOGLITAZONE; REPAGLINIDE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG APPROVAL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG COST; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLUID RETENTION; FRACTURE; GLUCOSE BLOOD LEVEL; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; MEDICAL SOCIETY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; SIDE EFFECT; SUSTAINED RELEASE FORMULATION; TREATMENT OUTCOME; WEIGHT GAIN; WEIGHT REDUCTION; BLOOD; COST BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; ECONOMICS; GREAT BRITAIN; METABOLISM; OBESITY;

COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; GREAT BRITAIN; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; OBESITY; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 84929889084     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(15)00053-4     Document Type: Note

References (11)

1. Inzucchi SE, Berganstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015, 38:140-149.
2. Type 2 diabetes in adults. Draft for consultation National Institute for Health and Care Excellence, (accessed March 1, 2015). https://www.nice.org.uk/guidance/gid-cgwave0612/resources/type-2-diabetes-guideline-consultation2.
3. O'Hare JP, Miller-Jones D, Hanif W, et al. The new NICE guidelines for type 2 diabetes-a critical analysis. Br J Diabetes Vasc Dis 2015, 15:3-7.
4. Price C NICE risks making itself a 'laughing stock' over guidance on metformin alternatives, say experts (accessed March 1, 2015). http://www.pulsetoday.co.uk/clinical/diabetes/nice-risks-making-itself-a-laughing-stock-over-guidance-on-metformin-alternatives-say-experts/20009139.article#.VOheRnyG-So.
5. Doctors outraged by NICE draft guidance on drug treatments for type 2 diabetes, online study shows Creation Pinpoint press office, (accessed March 1, 2015). http://www.creationpinpoint.com/doctors-outraged-nice-draft-guidance-drug-treatments-type-2-diabetes-online-study-shows/.
6. Eccles MP, Grimshaw JM, Shekelle P, Schünemann HJ, Woolf S Developing clinical practice guidelines: target audiences, identifying topics for guidelines, guideline group composition and functioning and conflicts of interest. Implement Sci 2012, 7:60.
7. Phung OJ, Scholle JM, Talwar M, Coleman CL Effect of noninsulin antidiabetic drugs added to metformin therapy on glycaemic control, weight gain, and hypoglycaemia in type 2 diabetes. JAMA 2010, 303:1410-1418.
8. Schwartz S, Fonseca V, Berner B, Cramer M, Chiang YK, Lewin A Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care 2006, 29:759-764.
9. Pioglitazone: summary of product characteristics Medicines and Healthcare Products Regulatory Agency, (accessed March 1, 2015). http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1401774709954.pdf.
10. Sun F, Chai S, Li L, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis. J Diabetes Res 2015, 2015:157201.
11. McEwan P, Gordon J, Evans M, Ward T, Bennett H, Bergenheim K Estimating cost-effectiveness in type 2 diabetes: the impact of treatment guidelines and therapy duration. Med Decis Making 2015, published online Jan 16. 10.1177/0272989X14565821.